Immix Biopharma (IMMX) Income from Non-Controlling Interests (2023 - 2024)
Quarterly results put Income from Non-Controlling Interests at -$12914.0 for Q2 2024, up 41.29% from a year ago — trailing twelve months through Dec 2024 was -$84987.0 (up 49.85% YoY), and the annual figure for FY2024 was -$84987.0, up 49.85%.
Immix Biopharma has reported Income from Non-Controlling Interests over the past 2 years, most recently at -$12914.0 for Q2 2024.
- Income from Non-Controlling Interests reached -$12914.0 in Q2 2024 per IMMX's latest filing, up from -$72073.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at -$12914.0 in Q2 2024 and bottomed at -$72073.0 in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | -13.75 Mn |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | - |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Immix Biopharma | 476.17 Mn | 476.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -12,914.00 |
| Mar 31, 2024 | -72,073.00 |
| Dec 31, 2023 | -65,862.00 |
| Sep 30, 2023 | -63,248.00 |
| Jun 30, 2023 | -21,996.00 |
| Mar 31, 2023 | -18,368.00 |